SHG:603676 - Tibet Weixinkang Medicine Co Ltd

Tibet Weixinkang Medicine Co L
Sector: Health Care, Industry: Pharmaceuticals

Add to Watchlist

•  Default
• New Watchlist

   

Yahoo Finance

• Summary
• Financials
• Dividend
• Prices
• Posts
• User
• Alerts

Balance Sheet Cash Flow Income Statement Key Ratios Personalized

Show %	2013 Q4	2014 Q4	2015 Q4	2016 Q1	2016 Q2	2016 Q3	2016 Q4	2017 Q1	2017 Q2	2017 Q3	2017 Q4	2018 Q1	2018 Q2	2018 Q3	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	Graph
Total Revenue	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	934.23M 17.7%	1B 7.2%	1.03B 3.2%	1.14B 10.4%	1.2B 5.3%	1.35B 12.3%	1.4B 3.7%	1.43B 2.5%	1.48B 3.2%	1.39B -5.9%
Cost of Revenue	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	488.19M 17.2%	516.86M 5.9%	500.4M -3.2%	552.92M 10.5%	575.92M 4.2%	632.73M 9.9%	662.88M 4.8%	682.63M 3.0%	705.85M 3.4%	685.04M -2.9%
Gross Profit	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	446.04M 18.3%	484.6M 8.6%	533.22M 10.0%	588.03M 10.3%	625.84M 6.4%	716.29M 14.5%	735.67M 2.7%	751.01M 2.1%	774.06M 3.1%	707.52M -8.6%
Total Expenses	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	846.3M 15.3%	908.69M 7.4%	936.24M 3.0%	1.03B 9.8%	1.07B 3.6%	1.16B 9.1%	1.23B 5.9%	1.24B 0.9%	1.28B 3.2%	1.23B -4.1%
Operating Expense	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	358.11M 12.9%	391.83M 9.4%	435.84M 11.2%	475.23M 9.0%	489.3M 3.0%	529.84M 8.3%	568.48M 7.3%	559.69M -1.5%	576.7M 3.0%	544.73M -5.5%
Operating Income	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	87.93M 46.7%	92.77M 5.5%	97.39M 5.0%	112.8M 15.8%	136.53M 21.0%	186.45M 36.6%	167.18M -10.3%	191.32M 14.4%	197.36M 3.2%	162.8M -17.5%
Net Income (Cont Operations)	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	82.34M -	-	95.91M -	-	145.56M -	-	176.96M -	-	207.99M -	-
Net Income	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	82.34M 24.7%	95.59M 16.1%	95.91M 0.3%	116.27M 21.2%	145.56M 25.2%	164.54M 13.0%	176.96M 7.5%	198.29M 12.1%	207.99M 4.9%	236.21M 13.6%
Basic EPS	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	0.2 33.3%	0.22 10.0%	0.23 4.5%	0.28 21.7%	0.34 21.4%	0.39 14.7%	0.41 5.1%	0.46 12.2%	0.48 4.3%	0.55 14.6%
Diluted EPS	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	0.2 33.3%	0.22 10.0%	0.23 4.5%	0.28 21.7%	0.34 21.4%	0.39 14.7%	0.41 5.1%	0.46 12.2%	0.48 4.3%	0.55 14.6%